poisar

Stocks · News reference

Kamada Expands Biosimilar Portfolio With Commercial Launch Of Two Additional New Products In Israel, Adding To Existing Portfolio Of Two Products

Benzinga Newsdesk

Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

KMDA
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference

    Kamada Ltd., a global biopharmaceutical company specializing in plasma-derived therapies, announced that CEO Amir London will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. The presentation will be webcast and available for 30 days. The company continues to focus on organic growth of its commercial portfolio, plasma collection operations, and pursuing M&A opportunities.

    KMDA